Lantheus To Acquire Evergreen Theragnostics; Reaffirms Guidance

(RTTNews) - Lantheus Holdings (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics, Inc. in an all-cash transaction consisting of an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments.

Evergreen is a clinical-stage radiopharmaceutical company engaged in Contract Development and Manufacturing services as well as drug discovery and commercialization of proprietary products. Evergreen is headquartered in Springfield, NJ in a state-of-the-art GMP radiopharmaceutical facility.

Also, Lantheus Holdings reaffirmed full-year and fourth quarter, 2024 financial guidance.

For More Such Health News, visit rttnews.com.